Lexicon Pharmaceuticals LXRX Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lexicon Pharmaceuticals's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lexicon Pharmaceuticals's cash & equivalents?
- Lexicon Pharmaceuticals (LXRX) reported cash & equivalents of $67.09M in Q1 2026.
- How has Lexicon Pharmaceuticals's cash & equivalents changed year-over-year?
- Lexicon Pharmaceuticals's cash & equivalents increased by 6.7% year-over-year, from $62.89M to $67.09M.
- What is the long-term trend for Lexicon Pharmaceuticals's cash & equivalents?
- Over 5 years (2020 to 2025), Lexicon Pharmaceuticals's cash & equivalents has grown at a -12.9% compound annual growth rate (CAGR), from $126.26M to $63.33M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.